0001493152-21-002636.txt : 20210204 0001493152-21-002636.hdr.sgml : 20210204 20210204160536 ACCESSION NUMBER: 0001493152-21-002636 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20210204 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210204 DATE AS OF CHANGE: 20210204 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MISONIX INC CENTRAL INDEX KEY: 0000880432 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY APPARATUS & FURNITURE [3821] IRS NUMBER: 112148932 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-10986 FILM NUMBER: 21591135 BUSINESS ADDRESS: STREET 1: 1938 NEW HIGHWAY CITY: FARMINGDALE STATE: NY ZIP: 11735 BUSINESS PHONE: (631) 694-9555 MAIL ADDRESS: STREET 1: 1938 NEW HIGHWAY CITY: FARMINGDALE STATE: NY ZIP: 11735 FORMER COMPANY: FORMER CONFORMED NAME: MEDSONIC INC DATE OF NAME CHANGE: 19930328 8-K 1 form8-k.htm
0000880432 false 0000880432 2021-02-04 2021-02-04 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): February 4, 2021

 

MISONIX, INC.

(Exact name of Registrant as specified in its charter)

  

Delaware   001-10986   84-1856018
(State or Other Jurisdiction   (Commission   (IRS Employer
of Incorporation)   File Number)   Identification Number)

 

1938 New Highway, Farmingdale, New York   11735
(Address of Principal Executive Offices)   (Zip Code)

 

 (631) 694-9555

 (Registrant’s Telephone Number, Including Area Code)

 

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol   Name of exchange on which registered
Common Shares, $0.0001 par value   MSON   The Nasdaq Global Market

  

 

 

 
 

 

Item 2.02. Results of Operations and Financial Condition.

 

On February 4, 2021, Misonix, Inc. (the “Company”) issued a press release announcing financial results of its quarter ended December 31, 2020. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K and incorporated herein by reference.

 

The information furnished pursuant to Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to liabilities under that section and shall not be deemed to be incorporated by reference into any document filed under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.   Description
     
99.1   Press Release dated February 4, 2021.
104   Cover Page Interactive Data File (embedded within the Inline XBRL)

 

 2 
   

  

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: February 4, 2021 Misonix, Inc.
       
    By: /s/ Joseph P. Dwyer
      Joseph P. Dwyer
      Chief Financial Officer

 

 3 

  

 EX-99.1 2 ex99-1.htm

 

Exhibit 99.1

 

 

MISONIX REPORTS FISCAL 2021 SECOND QUARTER FINANCIAL RESULTS

 

FARMINGDALE, N.Y., February 4, 2021 — Misonix, Inc. (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, today reported financial results for the fiscal 2021 second quarter ended December 31, 2020 as summarized below:

 

   Three Months Ended   Six Months Ended 
   December 31,   December 31, 
   2020   2019   2020   2019 
                 
Revenue  $18,256,410   $19,721,986   $35,991,752   $30,867,908 
Gross profit  $12,991,711   $13,776,878   $25,616,452   $21,686,153 
Gross profit percentage   71.2%   69.9%   71.2%   70.3%
Pretax loss  $(1,264,597)  $(5,088,973)  $(6,243,249)  $(7,377,481)
Income tax benefit  $-   $-   $-   $4,085,000 
Net loss  $(1,264,597)  $(5,088,973)  $(6,243,249)  $(3,292,481)
                     
EBITDA (1)  $802,564   $(3,290,062)  $(2,118,986)  $(5,082,177)
Adjusted EBITDA (1)  $1,555,575   $(1,925,410)  $(599,842)  $(1,617,966)

 

    December 31,    June 30, 
    2020    2020 
           
Cash and cash equivalents  $32,833,836   $37,978,809 
Current and Long Term Debt  $43,895,249   $43,695,249 

 

(1)Definitions and disclosures regarding non-GAAP financial information including reconciliations are included at the end of this press release.

 

Second Quarter Fiscal Year 2021 Highlights:

 

● The novel coronavirus disease (“COVID-19”) continued to materially impact the industry and Misonix’s business in the first and second quarters of fiscal 2021 as elective procedures were delayed in order to treat patients affected by the COVID-19 pandemic and to allow health providers to comply with new safety measures.
   
● Fiscal 2021 second quarter revenue of $18.3 million decreased 7.4%, compared to $19.7 million in the fiscal 2020 second quarter.

  ○ Domestic surgical revenue increased 19.8%
  ○ International revenue declined 23.1%
  ○ Domestic wound revenue declined 16.2%

 

● Gross profit percentage on sales for the fiscal 2021 second quarter increased approximately 130 basis points to 71.2%, compared with 69.9% in the fiscal 2020 first quarter.

 

 

 

 

● Operating expenses decreased 26.2% during the fiscal 2021 second quarter as compared with the fiscal 2020 second quarter, reflecting improved cost management, a net $1.2 million bad debt recovery in the fiscal 2021 second quarter, and $1.0 million contract asset write off in the prior year. Excluding the bad debt and contract asset activity, operating expenses were 15.0% lower during the second quarter compared to the prior year.
   
● Net loss for the fiscal 2021 second quarter narrowed to $1.3 million, or a loss of $0.07 per diluted share, compared to a net loss of $5.1 million, or a loss of $0.33 per diluted share, in the fiscal 2020 second quarter.
   
● Fiscal 2021 second quarter Adjusted EBITDA improved to positive $1.6 million, compared to an Adjusted EBITDA loss of $1.9 million in the fiscal 2020 second quarter.
   
● In December 2020, Misonix announced that the second largest U.S. commercial payer is now covering Theraskin for the treatment of all lower extremity wounds, expanding Theraskin’s coverage by approximately 32 million lives.

 

Stavros Vizirgianakis, President and Chief Executive Officer of Misonix stated, “While COVID-19 remains a challenge for the global healthcare industry, our fiscal 2021 second quarter results reflect the ongoing strong execution by our team in generating sequential growth in total product revenue since the peak of the pandemic in June, as well as significantly improved financial performance since that time. Notably, the meaningful measures we have taken to reduce costs and improve operating efficiencies over the past nine months, combined with our strong gross profit margin of approximately 70%, enabled us to achieve positive second fiscal quarter adjusted EBITDA.

 

“During the second fiscal quarter, the continued strength of neXus drove a year-over-year increase in domestic surgical revenue of nearly 20%, which is largely in-line with our historical growth levels, while domestic wound sales and international product sales remain more impacted by COVID-19. With the continued healthy adoption of neXus and a growing footprint from which to expand our business, we expect to return to pre-pandemic top-line growth when we return to a more normalized environment. As such, we remain focused on developing and refining our commercial infrastructure, including acquiring additional sales resources, to ensure that we are in the best position to drive market share gains and further adoption of our surgical and regenerative products as we emerge from the pandemic.

 

“As we enter the second half of fiscal 2021, we are excited about the opportunities to grow organically by leveraging our proprietary ultrasonic technology and expanding the procedures we participate in, as well as the potential for additional distribution partnerships to further our offering across both surgical and wound. We are actively managing the business to best position Misonix for the future and remain confident in our ability to achieve our goals for long-term profitable growth and enhanced shareholder value.”

 

 

 

 

Sales Performance Supplemental Data

 

   For the three months ended         
   December 31,   Net change 
   2020   2019   $   % 
Total                
Surgical  $10,119,125   $9,988,559   $130,566    1.3%
Wound   8,137,285    9,733,427    (1,596,142)   -16.4%
Total  $18,256,410   $19,721,986   $(1,465,576)   -7.4%
                     
Domestic:                    
Surgical  $6,771,467   $5,652,381   $1,119,086    19.8%
Wound   8,054,039    9,606,332    (1,552,293)   -16.2%
Total  $14,825,506   $15,258,713   $(433,207)   -2.8%
                     
International:                    
Surgical  $3,347,658   $4,336,178   $(988,520)   -22.8%
Wound   83,246    127,095    (43,849)   -34.5%
Total  $3,430,904   $4,463,273   $(1,032,369)   -23.1%

 

Joe Dwyer, Chief Financial Officer, added, “We are pleased with the healthy sequential growth in product revenue from $17.7 million in our fiscal first quarter to $18.3 million in the current quarter against the backdrop of a difficult operating environment. Notably, the actions we have taken since the beginning of the pandemic to streamline our cost structure enabled us to meaningfully lower cash used in operations to $1.4 million in the current quarter, and report positive Adjusted EBITDA of $1.6 million in the fiscal 2021 second quarter, compared to an Adjusted EBITDA loss of $1.9 million in the prior year. In addition, we continue to lower our cash burn, and have restructured our term debt to lower our borrowing rate, extend the maturity date, and extend the debt repayment schedule.

 

“With a strong balance sheet reflecting over $32 million in cash at December 31, 2020, we believe Misonix is well positioned to withstand the near-term challenges related to COVID-19 and remain confident in the long-term prospects of our business. Although it is difficult to predict what the impact of COVID-19 will be in the coming months, we are optimistic that procedural volumes will grow as we move further into the year, following broad vaccine distribution.”

 

Fiscal Second Quarter 2021 Conference Call and Webcast

 

Misonix will host a conference call and webcast today, February 4, 2021, at 4:30 p.m. ET to discuss its financial results and operations, and host a question and answer session. The dial-in number for the audio conference call is 866-248-8441 (domestic) or 323-289-6576 (international) conference ID: 2793331. Participants may also listen to a live webcast of the call at the Company’s website through the “Events and Presentations” section under “Investor Relations” at www.misonix.com. Following its completion, a replay of the webcast will be available for 30 days on the Company’s website, www.misonix.com.

 

About Misonix, Inc.

 

Misonix, Inc. (Nasdaq: MSON) is a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative tissue products. Its surgical team markets and sells BoneScalpel and SonaStar, which facilitate precise bone sculpting and removal of soft and hard tumors and tissue, primarily in the areas of neurosurgery, orthopedic, plastic and maxillo-facial surgery. The Company’s wound team markets and sells TheraSkin, Therion, TheraGenesis and SonicOne to debride, treat and heal chronic and traumatic wounds in inpatient, outpatient and physician office sites of service. At Misonix, Better Matters! That is why throughout the Company’s history, Misonix has maintained its commitment to medical technology innovation and the development of products that radically improve outcomes for patients. Additional information is available on the Company’s web site at www.misonix.com.

 

 

 

 

Safe Harbor Statement

 

With the exception of historical information contained in this press release, content herein may contain “forward looking statements” that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements include projections regarding Misonix’s future operating results, ability to grow revenue, and ability to maintain gross profit margins. These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, the impact of COVID-19, or other pandemics, including any increased rates of infection, and the impact of related governmental, individual and business responses. This includes our ability to obtain or forecast accurate surgical procedure volume in the midst of the COVID-19 pandemic; the risk that the COVID-19 pandemic could lead to further material delays and cancellations of, or reduced demand for, surgical procedures; curtailed or delayed capital spending by hospitals and surgical centers; potential closures of our facilities; delays in gathering clinical evidence; diversion of management and other resources to respond to the COVID-19 outbreak; the impact of global and regional economic and credit market conditions on healthcare spending; the risk that the COVID-19 virus disrupts local economies and causes economies in our key markets to enter prolonged recessions; the ability of our staff to travel to work; our ability to maintain adequate inventories and delivery capabilities; the impact on our customers and supply chain, and the impact on demand in general. These forward-looking statements are also subject to uncertainties and change resulting from delays and risks associated with the performance of contracts; risks associated with international sales and currency fluctuations; uncertainties as a result of research and development; acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy; risks involved in introducing and marketing new products; potential acquisitions; the entry of competitive products into the marketplace; consumer and industry acceptance; litigation and/or court proceedings, including the timing and monetary requirements of such activities; the timing of finding strategic partners and implementing such relationships; regulatory risks including clearance of pending and/or contemplated 510(k) filings; our ability to achieve and maintain profitability in our business lines; access to capital; and other factors described from time to time in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the fiscal year ended June 30, 2020, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking statements.

 

Contact:    
Joe Dwyer   Norberto Aja, Jennifer Neuman
Chief Financial Officer   JCIR
Misonix, Inc.  

212-835-8500 or mson@jcir.com

631-694-9555

 

 

 

 

Misonix, Inc. and Subsidiaries

Condensed Consolidated Statements of Operations

(Unaudited)

 

   For the three months ended   For the six months ended 
   December 31,   December 31, 
   2020   2019   2020   2019 
                 
Revenue  $18,256,410   $19,721,986   $35,991,752   $30,867,908 
Cost of revenue   5,264,699    5,945,108    10,375,300    9,181,755 
Gross profit   12,991,711    13,776,878    25,616,452    21,686,153 
                     
Operating expenses:                    
Selling expenses   8,423,075    11,800,565    19,392,753    17,001,147 
General and administrative expenses   3,918,950    5,149,715    8,371,277    9,357,522 
Research and development expenses   968,377    1,087,449    2,218,551    1,858,860 
Total operating expenses   13,310,402    18,037,729    29,982,581    28,217,529 
Loss from operations   (318,691)   (4,260,851)   (4,366,129)   (6,531,376)
                     
Other income (expense):                    
Interest income   2,920    5,293    4,012    24,170 
Interest expense   (949,105)   (833,035)   (1,882,828)   (869,132)
Other   279    (380)   1,696    (1,143)
Total other expense   (945,906)   (828,122)   (1,877,120)   (846,105)
                     
Loss from operations before income taxes   (1,264,597)   (5,088,973)   (6,243,249)   (7,377,481)
                     
Income tax benefit   -    -    -    4,085,000 
                     
Net loss  $(1,264,597)  $(5,088,973)  $(6,243,249)  $(3,292,481)
                     
Net loss per share:                    
Basic  $(0.07)  $(0.33)  $(0.36)  $(0.26)
Diluted  $(0.07)  $(0.33)  $(0.36)  $(0.26)
                     
Weighted average shares - Basic   17,217,948    15,222,870    17,215,817    12,439,860 
Weighted average shares - Diluted   17,217,948    15,222,870    17,215,817    12,439,860 

 

 

 

 

Misonix, Inc. and Subsidiaries

Condensed Consolidated Balance Sheets

 

   December 31,   June 30, 
   2020   2020 
    (Unaudited)      
Assets          
Current assets:          
Cash and cash equivalents  $32,833,836   $37,978,809 
Accounts receivable, less allowance for doubtful accounts of $2,202,392 and $2,573,968, respectively   11,077,214    11,064,768 
Inventories, net   13,222,262    14,010,684 
Prepaid expenses and other current assets   1,248,170    1,668,244 
Total current assets   58,381,482    64,722,505 
           
Property, plant and equipment, net of accumulated amortization and depreciation of $14,089,699 and $12,715,917, respectively   8,023,305    7,304,258 
Patents, net of accumulated amortization of $1,413,910 and $1,341,976, respectively   786,007    784,318 
Goodwill   108,234,664    108,310,350 
Intangible assets   20,485,417    21,281,136 
Lease right-of-use assets   1,202,017    1,098,830 
Other assets   246,230    322,310 
Total assets  $197,359,122   $203,823,707 
           
Liabilities and shareholders’ equity          
Current liabilities:          
Accounts payable  $2,656,252   $4,273,568 
Accrued expenses and other current liabilities   7,075,399    7,515,751 
Current portion of lease liabilities   508,870    414,058 
Current portion of notes payable   2,888,604    5,099,744 
Total current liabilities   13,129,125    17,303,121 
           
Non-current liabilities:          
Notes payable   41,006,645    38,595,505 
Lease liabilities   739,714    723,553 
Deferred tax liabilities   33,293    33,293 
Other non-current liabilities   498,938    516,665 
Total liabilities   55,407,715    57,172,137 
           
Commitments and contingencies          
           
Shareholders’ equity          
Common stock, $.0001 par value; shares authorized 40,000,000; 17,377,748 and 17,369,435 shares issued and outstanding in each period   1,738    1,737 
Additional paid-in capital   187,504,189    185,961,104 
Accumulated deficit   (45,554,520)   (39,311,271)
Total shareholders’ equity   141,951,407    146,651,570 
           
Total liabilities and shareholders’ equity  $197,359,122   $203,823,707 

 

 

 

 

Use of Non-GAAP Financial Measures

 

The Company has presented the following non-GAAP financial measures in this press release: EBITDA and Adjusted EBITDA. The Company defines EBITDA as the net income (loss) as reported under GAAP, plus depreciation and amortization expense, interest expense and income tax expense (benefit). The Company defines Adjusted EBITDA as EBITDA plus non-cash stock compensation expense and M&A transaction fees. Historically, the Company excluded bad debt expense from its calculation of Adjusted EBITDA by adding bad debt expense to EBITDA. Beginning with the quarter ended September 30, 2020, the Company will no longer exclude bad debt expense from the calculation Adjusted EBITDA, and prior comparative periods will be adjusted accordingly.

 

The Company has also provided below pro-forma revenue, which is also a non-GAAP financial measurement. The Company acquired the operations of Solsys Medical at the end of its first fiscal quarter ended September 30, 2019. The Company has presented pro forma revenue to show revenue on a comparable basis as if Solsys had been acquired at the beginning of the comparative periods presented.

 

We present these non-GAAP measures because we believe these measures are useful indicators of our operating performance. Our management uses these non-GAAP measures principally as a measure of our operating performance and believes that these measures are useful to investors because they are frequently used by analysts, investors and other interested parties to evaluate the operating performance of companies in our industry. We also believe that these measures are useful to our management and investors as a measure of comparative operating performance from period to period.

 

   Six Months Ended         
   December 31,   Net Change 
   2020   2019   $   % 
                 
Revenue as reported  $35,991,752   $30,867,908   $5,123,844    16.6%
Solsys revenue   -    8,344,795           
                     
Pro forma revenue  $35,991,752   $39,212,703   $(3,220,951)   -8.2%

 

   Three Months Ended   Six Months Ended 
   December 31,   December 31, 
   2020   2019   2020   2019 
                 
EBITDA:                    
Net loss  $(1,264,597)  $(5,088,973)  $(6,243,249)  $(3,292,481)
Income tax benefit   -    -    -    (4,085,000)
Depreciation and amortization   1,118,056    965,876    2,241,435    1,426,172 
Interest expense   949,105    833,035    1,882,828    869,132 
EBITDA   802,564    (3,290,062)   (2,118,986)   (5,082,177)
                     
Non-cash stock compensation   753,011    404,652    1,519,144    749,736 
Reserve for contract asset   -    960,000    -    960,000 
M&A transaction fees   -    -    -    1,754,475 
Adjusted EBITDA  $1,555,575   $(1,925,410)  $(599,842)  $(1,617,966)

 

 

 

 GRAPHIC 3 ex99-1_001.jpg begin 644 ex99-1_001.jpg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end EX-101.SCH 4 mson-20210204.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 mson-20210204_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 mson-20210204_pre.xml XBRL PRESENTATION FILE XML 7 form8-k_htm.xml IDEA: XBRL DOCUMENT 0000880432 2021-02-04 2021-02-04 iso4217:USD shares iso4217:USD shares 0000880432 false 8-K 2021-02-04 MISONIX, INC. DE 001-10986 84-1856018 1938 New Highway Farmingdale NY 11735 (631) 694-9555 false false false false false Common Shares, $0.0001 par value MSON NASDAQ XML 8 R1.htm IDEA: XBRL DOCUMENT v3.20.4
Cover
Feb. 04, 2021
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Feb. 04, 2021
Entity File Number 001-10986
Entity Registrant Name MISONIX, INC.
Entity Central Index Key 0000880432
Entity Tax Identification Number 84-1856018
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 1938 New Highway
Entity Address, City or Town Farmingdale
Entity Address, State or Province NY
Entity Address, Postal Zip Code 11735
City Area Code (631)
Local Phone Number 694-9555
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Shares, $0.0001 par value
Trading Symbol MSON
Security Exchange Name NASDAQ
Entity Emerging Growth Company false

EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( +& 1%('04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " "Q@$128;ML?^\ K @ $0 &1O8U!R;W!S+V-O&ULS9+! M3L,P#(9?!>7>.FUAAZC+91,GD)"8!.(6)=X6K6FBQ*C=V].&K1."!^ 8^\_G MSY);'83V$5^B#QC)8KH;7=,!@M(G M=4"H.5^!0U)&D8(96(2%R&1KM- 1%?EXP1N]X,-G[#+,:, .'?:4H"HK8'*> M&,YCU\(-,,,(HTO?!30+,5?_Q.8.L$MR3'9)#<-0#DW.33M4\/[\])K7+6R? M2/4:IU_)"CH'7+/KY+=FL]T],EGSNBIX7?#[7;42_$$T]&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M M3A^%$5B-;'EDD81_OTV23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R M> +]O6N[!3+ MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,! M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2 MBW A(5M>5 TR M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$ MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7K;YH] M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZKR2.FJW"$2M"/F(9 M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+ MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+ M.7\N?<^E[[GT/:'2MSAD6R4)RU3393>* M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.WF)&Y M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_# M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0 MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYNTB42%(JP# 4A M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.' MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_ M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]! MU4#E/]O4#6CV#30,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04 M" "Q@$121LNI*C,$ J$ & 'AL+W=O_0L/T8G>&Q)8QQ.P09@A)NLQN" UIMQ_3"V$+T*PMN;(< MX-_WR!";;LTQ+1=@V3ZO'QW)[Y$8;)3^EJTY-V2;Q#*[::V-23\Z3A:N><*R M*Y5R"5>62B?,0%.OG"S5G$5%4!([GNOVG(0)V1H.BG,S/1RHW,1"\IDF69XD M3.]N>:PV-RW:>COQ+%9K8T\XPT'*5GS.S<_I3$/+*54BD7"9"26)YLN;UHA^ MO/5\&U#<\8O@F^SHF-BN+)3Z9AN3Z*;E6B(>\]!8"08_KWS,X]@J <=?!]%6 M^4P;>'S\IOY0=!XZLV 9'ZOXJXC,^J85M$C$ERR/S;/:?.*'#G6M7JCBK/@F MF_V]OM\B89X9E1R"@2 1(< K^#>/ZB@O&.�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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.4 html 1 96 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://misonix.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm ex99-1.htm mson-20210204.xsd mson-20210204_lab.xml mson-20210204_pre.xml http://xbrl.sec.gov/dei/2020-01-31 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form8-k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "form8-k.htm" ] }, "labelLink": { "local": [ "mson-20210204_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "mson-20210204_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "mson-20210204.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "MSON", "nsuri": "http://misonix.com/20210204", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2021-02-04to2021-02-04", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://misonix.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2021-02-04to2021-02-04", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://misonix.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://misonix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://misonix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://misonix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://misonix.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://misonix.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://misonix.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://misonix.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r9", "r11", "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://misonix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://misonix.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://misonix.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://misonix.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://misonix.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://misonix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://misonix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://misonix.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://misonix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://misonix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://misonix.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://misonix.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://misonix.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://misonix.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://misonix.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://misonix.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://misonix.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://misonix.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://misonix.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://misonix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://misonix.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://misonix.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://misonix.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://misonix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://misonix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://misonix.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://misonix.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://misonix.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://misonix.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://misonix.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://misonix.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://misonix.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://misonix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://misonix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://misonix.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://misonix.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://misonix.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://misonix.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://misonix.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://misonix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://misonix.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://misonix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://misonix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://misonix.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://misonix.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://misonix.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://misonix.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://misonix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://misonix.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://misonix.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r11": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r12": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r13": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r14": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r15": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r16": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r17": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r18": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" } }, "version": "2.1" } ZIP 15 0001493152-21-002636-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-21-002636-xbrl.zip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end